Novel 4-Azapregnene Derivatives as Potential Anticancer Agents: Synthesis, Antiproliferative Activity and Molecular Docking Studies

Molecules. 2022 Sep 19;27(18):6126. doi: 10.3390/molecules27186126.

Abstract

A series of novel 21E-arylidene-4-azapregn-5-ene steroids has been successfully designed, synthesized and structurally characterized, and their antiproliferative activity was evaluated in four different cell lines. Within this group, the 21E-(pyridin-3-yl)methylidene derivative exhibited significant cytotoxic activity in hormone-dependent cells LNCaP (IC50 = 10.20 µM) and T47-D cells (IC50 = 1.33 µM). In PC-3 androgen-independent cells, the steroid 21E-p-nitrophenylidene-4-azapregn-5-ene was the most potent of this series (IC50 = 3.29 µM). Considering these results, the 21E-(pyridin-3-yl)methylidene derivative was chosen for further biological studies on T47-D and LNCaP cells, and it was shown that this azasteroid seems to lead T47-D cells to apoptotic death. Finally, molecular docking studies were performed to explore the affinity of these 4-azapregnene derivatives to several steroid targets, namely 5α-reductase type 2, estrogen receptor α, androgen receptor and CYP17A1. In general, compounds presented higher affinity to 5α-reductase type 2 and estrogen receptor α.

Keywords: 4-azapregnenes; 4-azasteroids; aldol condensation; antiproliferative activity; molecular docking.

MeSH terms

  • Androgens / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Azasteroids / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Cholestenone 5 alpha-Reductase / metabolism
  • Drug Screening Assays, Antitumor
  • Estrogen Receptor alpha
  • Molecular Docking Simulation
  • Molecular Structure
  • Receptors, Androgen* / metabolism
  • Structure-Activity Relationship

Substances

  • Androgens
  • Antineoplastic Agents
  • Azasteroids
  • Estrogen Receptor alpha
  • Receptors, Androgen
  • Cholestenone 5 alpha-Reductase